News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Raises Targets for Victoza and Insulin Demand


8/9/2012 7:21:26 AM

Danish drugmaker Novo Nordisk raised its full-year guidance on Thursday after a rise in sales of diabetes drug Victoza and synthetic insulins boosted second-quarter sales and operating profit, beating forecasts. Novo, the world's biggest insulin producer, said sales of Victoza jumped 83 percent and sales of modern insulins -- synthetic rather than human hormones -- grew 23 percent, both exceeding forecasts. The company is benefiting from a boom in diabetes treatments linked to growing obesity rates worldwide. "It is a very strong result which clearly exceed expectations that were already high," said Sydbank analyst Soren Hansen.

Read at Reuters
Read at Market Watch
Read at Chicago Tribune
Read at Washington Post
Read at BusinessWeek

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES